Market Research Industry Reports

Stada Arzneimittel AG (SAZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers a portfolio of products in various therapeutic categories including pain, womens health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Pantoprazol, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium, and Vitaprost. The company operates in more than 30 countries with sales in Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG (SAZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 11
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 14
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 15
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 16
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 17
Private Equity 19
Ardian May Sell Riemser Pharma for USD494.3 Million 19
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 21
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 22
Partnerships 24
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 24
Theratechnologies Enters into Commercialization Agreement with BL&H 25
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 26
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 27
Licensing Agreements 28
BL&H Enters into Licensing Agreement with Race Oncology 28
BL&H Enter into Licensing Agreement with MDNA Life Sciences 29
Thornton & Ross Enters into Licensing Agreement with Futura Medical 30
BL&H Enters into Licensing Agreement with Telesta Therapeutics 31
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 32
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 33
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 34
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 35
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 37
Equity Offering 38
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 38
Debt Offering 39
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 39
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 40
Asset Transactions 41
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 41
Acquisition 42
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 42
Elliott Management May acquire Stake in Stada Arzneimittel 43
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 44
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 45
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 46
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 48
Stada Arzneimittel AG - Key Competitors 49
Stada Arzneimittel AG - Key Employees 50
Stada Arzneimittel AG - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Recent Developments 54
Financial Announcements 54
Mar 08, 2018: STADA records positive business development in 2017 54
Nov 09, 2017: STADA shows good business development in the third quarter of 2017 and the first nine months 57
Corporate Communications 59
Apr 16, 2018: Changes in the management team of STADA 59
Feb 01, 2018: Supervisory Board of STADA Arzneimittel appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 60
Feb 01, 2018: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018 61
Jul 04, 2017: STADA Arzneimittel appoints new Chief Executive Officer and Chief Financial Officer incumbents step down from their positions 62
Apr 24, 2017: Dr. Ralph Grobecker to become Managing Director of STADAs OTC segment 63
Product News 64
11/21/2017: U.S. FDA Accepts Regulatory Submission and Grants Priority Review for US WorldMeds Lofexidine 64
03/27/2018: FDA Advisory Committee Votes in Favor of LUCEMYRA (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms 65
Other Significant Developments 66
Mar 08, 2018: CEO Albrecht to modernize STADA Biosimilars to focus on oncology, CNS, diabetes and ophthalmology 66
Aug 03, 2017: STADA shows good operational development in first six months of 2017 67
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List Of Tables

List of Tables
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stada Arzneimittel AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stada Arzneimittel AG, Deals By Therapy Area, 2012 to YTD 2018 9
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 11
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
STADA Arzneimittel Acquires AndroDoz and NeroDoz from OOO PharmEnergy for USD7.9 Million 14
Thornton & Ross Acquires Rights for Flexitol from LaCorium Health for USD17 Million 15
STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For US$108 Million 16
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 17
Ardian May Sell Riemser Pharma for USD494.3 Million 19
Bain Capital and Cinven Partners to Acquire Stada Arzneimittel 21
Bain Capital Private Equity and Cinven Partners Renew the Terms to Acquire Stada Arzneimittel 22
Enzymatica Enters into Distribution Agreement with STADA for ColdZyme 24
Theratechnologies Enters into Commercialization Agreement with BL&H 25
Stada Arzneimittel to Form Joint Venture with Hetero Drugs 26
Claris Lifesciences Enters into Distribution Agreement with Stada Arzneimittel 27
BL&H Enters into Licensing Agreement with Race Oncology 28
BL&H Enter into Licensing Agreement with MDNA Life Sciences 29
Thornton & Ross Enters into Licensing Agreement with Futura Medical 30
BL&H Enters into Licensing Agreement with Telesta Therapeutics 31
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 32
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 33
Stada Arzneimittel Enters into Licensing Agreement with Richter-Helm BioTec 34
Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 35
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 37
Telesta Therapeutics Raises USD0.2 Million in Private Placement of Shares 38
Stada Arzneimittel Announces Private Placement of Bonds Due 2022 for USD325.5 39
Stada Arzneimittel Completes Private Placement Of Bonds Due 2018 For US$452 Million 40
DMN Invest Acquires Two Drug Manufacturing Facilities From Stada Arzneimittel 41
Nidda Healthcare to Acquire Stake in Stada Arzneimittel 42
Elliott Management May acquire Stake in Stada Arzneimittel 43
STADA Arzneimittel to Acquire Laboratorio Vannier for USD13 Million 44
STADA Arzneimittel Acquires SCIOTEC Diagnostic Technologies for USD19.8 Million 45
Stada Arzneimittel Completes Acquisition Of Thornton & Ross, OTC Drug Maker, For US$339 Million 46
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 48
Stada Arzneimittel AG, Key Competitors 49
Stada Arzneimittel AG, Key Employees 50
Stada Arzneimittel AG, Subsidiaries 51

List Of Figures

List of Figures
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stada Arzneimittel AG, Medical Devices Deals, 2012 to YTD 2018 11

Stada Arzneimittel AG (SAZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are

USD 250View Report

Stada Arzneimittel AG Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Stada Arzneimittel AG Company Profile is a detailed strategic and analytical report on Stada Arzneimittel AG. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Stada Arzneimittel AG (SAZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are

USD 250View Report

Stada Arzneimittel AG Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Stada Arzneimittel AG Company Profile is a detailed strategic and analytical report on Stada Arzneimittel AG. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :70
Country :Germany
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube